Mounjaro and Trazodone Interaction: What Patients and Prescribers Need to Know

What is the interaction between Mounjaro and trazodone?

Mounjaro is tirzepatide, a once-weekly GIP and GLP-1 receptor agonist approved to improve glycemic control in adults and children 10 and older with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk for them [1]. The Mounjaro label carries no weight-loss indication [1]. Trazodone is an antidepressant whose current tablet label lists one indication, major depressive disorder in adults [2].

Neither label names the other drug. Mounjaro's drug interactions section covers insulin and insulin secretagogues, and oral medicines generally, because tirzepatide delays gastric emptying [1]. Trazodone's interaction table lists MAOIs, other serotonergic drugs, antiplatelet agents and anticoagulants, strong CYP3A4 inhibitors, strong CYP3A4 inducers, digoxin and phenytoin, CNS depressants, and QT-prolonging drugs; tirzepatide is not named in any of those groups [2].

Does Mounjaro change trazodone blood levels?

There are two possible routes, and they work differently.

The enzyme route is the clearer one. Tirzepatide is not broken down by cytochrome P450 enzymes; the label describes proteolytic cleavage of the peptide backbone, beta-oxidation of its fatty diacid and amide hydrolysis, with low in vitro potential to inhibit or induce CYP enzymes [1]. Trazodone is a CYP3A4 substrate: in human liver microsomes and expressed enzymes, only CYP3A4 produced its active metabolite mCPP [3], and the label describes trazodone only as a drug whose levels other medicines can change, not as an inhibitor or inducer [2]. A 2025 in vitro study found CYP2D6, CYP2C19 and flavin monooxygenases contribute to other, inactive metabolites, with CYP3A4 still the primary enzyme [4].

The absorption route is less predictable. The Mounjaro label states that tirzepatide delays gastric emptying and that the delay is largest after the first dose and diminishes over time [1]. It advises monitoring oral medicines that depend on threshold concentrations for efficacy and those with a narrow therapeutic index, such as warfarin [1]. The label's own demonstration: a single 5 mg dose lowered acetaminophen peak concentration by 55% and pushed the time to peak 1 hour later, while after 6 weeks on 15 mg weekly there was no meaningful effect on acetaminophen peak or time to peak and total exposure was unchanged [1].

Trazodone on its own peaks about 1 hour after a dose on an empty stomach and about 2 hours with food; in 8 healthy volunteers, food lowered the peak from 1.88 to 1.47 micrograms/mL and delayed it from 1.3 to 2.0 hours without changing total absorption [2][5]. The trazodone label says to take it shortly after a meal or light snack [2].

Sedation, dizziness and standing blood pressure

The trazodone label links the drug's alpha-1 adrenergic blockade to postural hypotension [2]. In controlled outpatient trials (157 on trazodone, 158 on placebo), drowsiness was reported by 41% versus 20%, dizziness or lightheadedness 28% versus 15%, hypotension 4% versus 0%, syncope 5% versus 1%, and blurred vision 15% versus 4% [2]. The label also warns that trazodone can impair judgment, thinking and motor skills and says patients should use caution when operating machinery, and says it may enhance the effects of alcohol, barbiturates and other CNS depressants [2].

Mounjaro's common adverse reactions are gastrointestinal. In the label's pooled placebo-controlled trials in adults with type 2 diabetes (235 on placebo; 237 on 5 mg, 240 on 10 mg, 241 on 15 mg), nausea was 4% versus 12%, 15% and 18%, vomiting 2% versus 5%, 5% and 9%, and diarrhea 9% versus 12%, 13% and 17% [1]. The label warns of acute kidney injury from volume depletion in patients with gastrointestinal reactions and says to monitor renal function in those patients [1].

Is serotonin syndrome a concern with this pair?

The trazodone label calls serotonin syndrome potentially life-threatening and says it can occur with trazodone alone; the risk rises with triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone and St John's wort, and MAOIs are contraindicated [2]. Listed signs include agitation, hallucinations, tachycardia, labile blood pressure, sweating, fever, tremor, rigidity, myoclonus, seizures, and nausea, vomiting or diarrhea [2].

Tirzepatide is a GIP and GLP-1 receptor agonist [1]. Trazodone's labeled list of serotonergic drugs does not name it, and no interaction between the two is named in either label [1][2].

Heart rhythm

Trazodone prolongs the QT/QTc interval. The label says to avoid it in people with known QT prolongation, a history of cardiac arrhythmia, low potassium or magnesium, or congenital long QT, and during the initial recovery phase after a myocardial infarction, and to avoid combining it with other QT-prolonging drugs [2]. Postmarketing reports include torsades de pointes and ventricular tachycardia at doses of 100 mg per day or less with the immediate-release tablets [2]. Tirzepatide is not among the QT-prolonging drugs listed in the trazodone label [2].

Blood sugar and hypoglycemia

The Mounjaro label warns that hypoglycemia risk rises when it is used with an insulin secretagogue such as a sulfonylurea or with insulin, and that reducing those doses may be necessary [1]. Trazodone's interaction table does not list insulin, sulfonylureas or other glucose-lowering drugs [2].

Is the combination contraindicated?

Trazodone's only contraindication is use with an MAOI, or within 14 days of stopping one, including linezolid and intravenous methylene blue [2]. Mounjaro's contraindications are a personal or family history of medullary thyroid carcinoma or MEN 2, and serious hypersensitivity to tirzepatide or an excipient [1]. Neither label lists the other drug among its contraindications [1][2].